Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 1/20 | 0.35 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9359356 | 0.90 | STS (0.31) | STS | |
| SCHEMBL31065699 | 0.84 | STS (0.38) | STSCYP2B6SIGMAR1CA1CA9 | |
| SCHEMBL30861784 | 0.78 | — | — | |
| SCHEMBL30861783 | 0.78 | — | — | |
| SCHEMBL22031973 | 0.77 | STS (0.40) | STSCYP2B6 | |
| SCHEMBL22124456 | 0.74 | MAOB (0.36) | STSCYP2B6 | |
| SCHEMBL32679176 | 0.72 | CYP2B6 (0.42) | STSCYP2B6CA1CA9 | |
| SCHEMBL4889047 | 0.72 | CYP2B6 (0.42) | STSCYP2B6CA1CA9 | |
| SCHEMBL2289350 | 0.72 | CYP2B6 (0.42) | STSCYP2B6CA1CA9 | |
| SCHEMBL20537304 | 0.72 | CYP2B6 (0.38) | STSCYP2B6CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-8349864-B2 | Pyrano [3,2-C] pyridones and related heterocyclic compounds as pharmaceutical agents for treating disorders responsive to apoptosis, antiproliferation or vascular disruption, and the use thereof | NEW MEXICO TECHNICAL RESEARCH FOUNDATION (US) | 2013-01-08 | — | — | US | disclosed |
| US-20090247566-A1 | Pyrano [3,2-C] Pyridones and Related Heterocyclic Compounds as Pharmaceutical Agents for Treating Disorders Responsive to Apoptosis, Antiproliferation or Vascular Disruption, and the Use Thereof | NEW MEXICO TECHNICAL RESEARCH FOUNDATION | 2009-10-01 | — | — | US | disclosed |
| EP-0427606-B1 | 4-Amidino chromane and 4-amidino pyrano(3,2-c)pyridine derivatives, process for preparation and pharmaceutical compositions containing them | SANOFI SA (FR) | 1995-02-01 | — | — | EP | disclosed |
| EP-0327239-B1 | 1-carbacephalosporin antibiotics | LILLY CO ELI (US) | 1994-06-22 | — | — | EP | disclosed |
| EP-0259811-B1 | Physiologically active substance fa-4283, its derivatives and production thereof | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1994-01-12 | — | — | EP | disclosed |
| EP-0308792-B1 | AZACHROMANE DERIVATIVES | MERCK PATENT GmbH (DE) | 1993-07-28 | — | — | EP | disclosed |
| US-5116849-A | 4-AMIDINO CHROMAN AND 4-AMIDINO PYRANO (3,2-C) PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI (FR) | 1992-05-26 | — | — | US | disclosed |
| EP-0205292-B1 | Pyrano[3,2-c]pyridine derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1991-11-06 | — | — | EP | disclosed |
| US-5019571-A | 1-carbacephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1991-05-28 | — | — | US | disclosed |
| US-4902707-A | Bicyclic pyrazolidinones, compositions and use | ELI LILLY AND COMPANY (US) | 1990-02-20 | — | — | US | disclosed |
| WO-1989011477-A1 | BENZOXEPINE AND RELATED COMPOUNDS | BEECHAM GROUP PLC (GB) | 1989-11-30 | — | — | WO | disclosed |
| WO-1989010925-A1 | NOVEL COMPOUNDS AND TREATMENT | BEECHAM GROUP PLC (GB) | 1989-11-16 | — | — | WO | disclosed |
| EP-0327239-A1 | 1-carbacephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1989-08-09 | — | — | EP | disclosed |
| EP-0308792-A2 | Azachromane derivatives | MERCK PATENT GmbH (DE) | 1989-03-29 | — | — | EP | disclosed |
| US-4803275-A | FAT BIOSYNTHESIS INHIBITOR | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-02-07 | — | — | US | disclosed |
| EP-0259811-A2 | Physiologically active substance fa-4283, its derivatives and production thereof | Takeda Chemical Industries, Ltd. (JP) | 1988-03-16 | — | — | EP | disclosed |
| EP-0205292-A2 | Pyrano[3,2-c]pyridine derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1986-12-17 | — | — | EP | disclosed |
| EP-0203722-A1 | Bicyclic pyrazolidinones | ELI LILLY AND COMPANY (US) | 1986-12-03 | — | — | EP | disclosed |
| EP-0202046-A1 | 7-Substituted bicyclic pyrazolidinones | ELI LILLY AND COMPANY (US) | 1986-11-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | STS 1795/4885CYP2B6 2968/4885SIGMAR1 3601/4885 |
| US-20090247566-A1 | Pyrano [3,2-C] Pyridones and Related Heterocyclic Compounds as Pharmaceutical Agents for Treating Disorders Responsive to Apoptosis, Antiproliferation or Vascular Disruption, and the Use Thereof | BAX, CASP3, CASP7 | STS 2663/4885CYP2B6 540/4885SIGMAR1 3172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.